Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2025, for NanoVibronix, Inc. (trading symbol: NAOV). The filing reflects the consummation of the "ENvue Merger" on February 14, 2025, where NanoVibronix acquired ENvue Medical Holdings LLC, a company focused on enteral feeding medical devices. The company operates two primary segments: NanoVibronix (non-invasive pain therapy and wound healing) and ENvue. The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2025 | Nine Months Ended Sept 30, 2025 | Dec 31, 2024 (Balance Sheet) |
|---|---|---|---|
| Revenue | $722,000 | $2,241,000 | N/A |
| Gross Profit | $189,000 | $523,000 | N/A |
| Net Income (Loss) | $510,000 | $(5,333,000) | N/A |
| Net Loss to Common Stockholders | $(780,000) | $(3,152,000) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $6,950,000 |
| Total Assets | N/A | N/A | $54,383,000 |
| Total Liabilities | N/A | N/A | $11,919,000 |
| Accumulated Deficit | N/A | N/A | $(76,858,000) |
Liquidity and Debt: As of September 30, 2025, the company held $6.95 million in cash and cash equivalents. Current liabilities totaled $11.64 million, including $3.73 million in warranty liabilities and $2.0 million in tranche financing liabilities. The company has an accumulated deficit of $76.86 million.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 92% year-over-year for the quarter ($722k vs. $376k) and 6% for the nine-month period ($2.24M vs. $2.11M), driven primarily by the inclusion of ENvue sales.
- Profitability Shift: The company reported a net income of $510,000 for the quarter, compared to a net loss of $998,000 in the prior year quarter. This was largely due to a $2.85 million gain from the change in fair value of warrant liabilities. However, the nine-month period showed a net loss of $5.33 million, up from $2.27 million in the prior year.
- Expense Increases: Operating expenses surged due to the merger. Selling and marketing expenses increased 349% for the quarter, and General and Administrative (G&A) expenses increased 108%, primarily due to ENvue integration and professional fees.
- Balance Sheet Expansion: Total assets grew from $3.63 million at year-end 2024 to $54.38 million at September 30, 2025, driven by the acquisition of ENvue, which added $38.6 million in goodwill and $5.3 million in intangible assets.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern for the next twelve months due to recurring losses and negative cash flows from operations ($6.7 million used in the first nine months of 2025). Future operations depend on raising additional capital.
- Unusual Items:
- Warrant Liability Gain: A significant non-cash gain of $3.2 million (quarter) and $4.6 million (nine months) was recorded due to the change in fair value of warrant liabilities.
- Inventory Write-down: The company recorded a $119,000 inventory write-down for the PainShield MD Plus product after submitting a request to the FDA to withdraw its clearance due to inaccuracies in the 510(k) application. Future sales of this product have been halted.
- Preferred Stock Dividends: Significant dividends were accrued on Series X (8%) and Series H (9%) preferred stock, reducing net income available to common stockholders.
- Risks:
- Legal Proceedings: An arbitration award of approximately $2.2 million (including interest) has been accrued regarding a dispute with Protrade Systems, Inc. The company is appealing the decision.
- Accounting Firm: The company dismissed its prior auditor, Zwick CPA, PLLC, in August 2025 due to potential proceedings against the firm. This may impact future filings and access to capital markets.
- Geopolitical: Operations in Israel face risks from ongoing regional conflicts.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $6.95 million cash balance against the $6.7 million operating cash burn rate for the first nine months of 2025.
- Warrant Liability Volatility: Assess the sustainability of net income, which is currently propped up by non-cash gains from warrant liability revaluation rather than core operations.
- Protrade Litigation: Monitor the status of the appeal regarding the $2.2 million arbitration award and potential cash outflows.
- Preferred Stock Dilution: Review the terms of Series X and Series H preferred stock, including high dividend rates (8-9%) and anti-dilution provisions that may significantly dilute common shareholders.
- Auditor Transition: Confirm the appointment and status of the new independent registered public accounting firm to ensure timely future SEC filings.